Chemistry:Zastaprazan

From HandWiki

Zastaprazan (trade name Jaqbo) is a pharmaceutical drug for gastrointestinal disorders. It is classified as a potassium-competitive acid blocker.[1][2] In April 2024, it was approved for use in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD).[3] In addition, it is in Phase III clinical trials for gastric ulcer and peptic ulcer.[4]

References

  1. ↑ "Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers". CPT: Pharmacometrics & Systems Pharmacology 13 (12): 2150–2158. December 2024. doi:10.1002/psp4.13228. PMID 39268835. 
  2. ↑ "Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease". Expert Opinion on Drug Metabolism & Toxicology 21 (1): 53–68. September 2024. doi:10.1080/17425255.2024.2397433. PMID 39189409. 
  3. ↑ "Zastaprazan: First Approval". Drugs 84 (7): 863–866. July 2024. doi:10.1007/s40265-024-02057-w. PMID 38916840. 
  4. ↑ "Zastaprazan". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800044958. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Zastaprazan&oldid=4036408"